Login to Your Account


DUBLIN – Shares in Neovacs SA surged Tuesday on news of an option agreement in China worth up to €65 million in up-front and milestone payments for IFNα Kinoid.

TOKYO – Exelixis Inc. and Takeda Pharmaceutical Co. Ltd. reached an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib.

With a pair of drugs devoted to what Ionis Pharmaceuticals Inc. CEO Stanley Crooke called "systematically knocking off the remaining lipid risk factors" for patients facing CV trouble, the company closed a potential $1.6 billion deal with Novartis AG.

More DEALS AND M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: